Connect with us

International

New typhoid conjugate vaccine Bio-TCV® approved in Indonesia

November 9, 2023, SEOUL, Republic of Korea and BANDUNG, Indonesia — The International Vaccine Institute (IVI), an international organization with a mission…

Published

13 mins ago

on

November 9, 2023, SEOUL, Republic of Korea and BANDUNG, Indonesia — The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and Bio Farma, a biotechnology company based in West Java, Indonesia, announced today that Bio Farma’s Bio-TCV® typhoid conjugate vaccine (TCV) was licensed in Indonesia following marketing approval from Badan Pengawas Obat dan Makanan (BPOM), the national regulatory authority.

Credit: Bio Farma

November 9, 2023, SEOUL, Republic of Korea and BANDUNG, Indonesia — The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and Bio Farma, a biotechnology company based in West Java, Indonesia, announced today that Bio Farma’s Bio-TCV® typhoid conjugate vaccine (TCV) was licensed in Indonesia following marketing approval from Badan Pengawas Obat dan Makanan (BPOM), the national regulatory authority.

 

Bio-TCV® is a Vi polysaccharide vaccine conjugated to the diphtheria toxoid carrier protein (Vi-DT), initially developed at IVI and transferred to Bio Farma in 2014. From the outset, the scope of the joint vaccine development program included preclinical development and Phase I-III clinical trials followed by technical support through local licensure and submission for prequalification (PQ) from the World Health Organization (WHO), a designation that enables agencies such as Gavi, the Vaccine Alliance to purchase the vaccine for global public health use. This decade-long partnership in pursuit of another safe, effective, and affordable TCV has been in part funded by a grant from the Bill & Melinda Gates Foundation.

 

Dr. Sushant Sahastrabuddhe, Acting Deputy Director General, Clinical, Assessment, Regulatory, Evaluation at IVI, said: “We join Bio Farma in celebrating today’s exciting news of Bio-TCV®’s local licensure, a milestone after nearly a decade of collaboration. We’re grateful to the Bill & Melinda Gates Foundation for funding support of this vaccine development program, and to the project sites across Indonesia for their partnership. With emerging evidence that climate change and the increasing rise of antimicrobial resistance are impacting the prevalence and severity of typhoid fever, prevention of disease through vaccination is a key measure for typhoid control. We look ahead now to Bio-TCV®’s WHO PQ and introduction to the global health market.”

 

Shadiq Akasya, President Director of Bio Farma, said: “Through good collaboration with IVI, Bio Farma has been able to successfully develop typhoid conjugate vaccine (Bio-TCV). Licensure of our typhoid conjugate vaccine (Bio-TCV) from our National Agency for Drug and Food Control (BPOM) has added yet another product to our product portfolio. Bio-TCV will undoubtedly be an important tool in the prevention of typhoid infection affording protection against this disease as early as 9 months of age. The successful development of Bio-TCV is testament to Bio Farma’s commitment to global health; combating infectious diseases through the provision of safe and efficacious vaccines that comply with international standards of quality.”

 

Dr. Duncan Steele, Deputy Director and Strategic Lead of Enteric Vaccines at the Bill & Melinda Gates Foundation, said: “We celebrate the licensure of Bio-TCV in Indonesia, another milestone for PT Bio Farma in their licensed vaccines and another great example of partnerships making the difference to advance vaccines for public health use. IVI’s leadership in developing and transferring the technology to Bio Farma is a credit to both organizations.”

 

IVI and Bio Farma confirmed the safety and immunogenicity of a single dose of Vi-DT and its non-inferiority to a control WHO-prequalified TCV in a Phase III clinical trial across three provincial capital cities in Indonesia. With the results of this study, BPOM approved the vaccine for national use in individuals ages 9 months to 45 years. Bio Farma will submit the dossier for WHO PQ, which, if achieved, will add an affordable TCV to the global public market that will be made available to low-income countries through Gavi, the Vaccine Alliance.

 

Typhoid fever is a potentially life-threatening febrile illness caused by Salmonella typhi that particularly affects children and young adults. According to the WHO, there are an estimated 11 to 20 million typhoid cases every year, largely in low- and middle-income countries. Vaccination has been shown to be an effective preventive strategy in controlling typhoid fever, though there are only two vaccines prequalified by the WHO at this time. IVI is working with vaccine manufacturers around the world to make more TCVs available in the public market.

 

 

###

 

 

About the International Vaccine Institute (IVI)

The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.

IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that is currently under assessment for WHO PQ.

IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.

 

 

About Bio Farma

PT Bio Farma (Persero) referred to as “Bio Farma” is a state-owned vaccine and antisera manufacturer for humans in Indonesia. Celebrating its 133th anniversary, Bio Farma has through the years grown into a life science company of international recognition producing and distributing more than 3.2 billion doses of vaccines per year. Bio Farma is by far the largest vaccine manufacturer in Southeast Asia. The company supplies not only the needs for Expanded Program on Immunization (EPI) in Indonesia but also the global market to more than 150 countries. Bio Farma’s ability to enter the global market is due to numerous of its vaccines attaining pre-qualification (PQ) from World Health Organization (WHO). The Bill & Melinda Gates Foundation and PATH have collaborated with Bio Farma to produce novel Oral Polio Vaccine type 2 (nOPV2) in support of Global Polio Eradication Initiative (GPEI); it was the first vaccine granted the EUL designation from WHO in 2020.   

Bio Farma plays an important role in establishing a healthy nation in which its existence would be maintained for generations to come. With its philosophy of “Dedicated to improving Quality of Life” Bio Farma stands firm in devoting its efforts to Global Health Security.

In early 2020, a state-owned pharmaceutical holding company was established with Bio Farma as its parent company. The establishment of this holding company is aimed to strengthen self-reliance of the national pharmaceutical industry, and also to increase the availability of products supporting the pharmaceutical ecosystem. For more information refer to: www.biofarma.co.id

 

 

 

CONTACT

 

IVI:

Aerie Em, Global Communications & Advocacy Manager
+82 2 881 1386 | aerie.em@ivi.int

 

Bio Farma:
Iwan Setiawan, Corporate Secretary

+62 81321174856  iwan.setiawan@biofarma.co.id

 

Read More

Related Topics:
Continue Reading

International

Financial Assets Are Running Out Of Steam For Now

Financial Assets Are Running Out Of Steam For Now

Authored by Simon White, Bloomberg macro strategist,

The impressive rally in stocks and…

Published

1 hour ago

on

November 9, 2023

By

Financial Assets Are Running Out Of Steam For Now

Authored by Simon White, Bloomberg macro strategist,

The impressive rally in stocks and bonds over the last week or two is likely to take a breather, with both assets now overbought in the short term.

Bonds have been deeply oversold since last year, but the latest rally to ~4.5% in the 10-year has taken Treasuries to only one standard deviation below their long-term mean growth level (back towards the range they normally inhabited before the extremes of the pandemic).

The stock rally in recent months has taken the S&P back to near its long-term average growth level of 10% on an annual basis.

Overall this leaves the stock-bond ratio a little overbought, so it may come off a little more.

But it is looking less likely the NBER will call a recession for most of next year, meaning the stock-bond ratio should resume its rise.

Not much from a data perspective is likely to move the dial for the balance of this week, with only initial jobless claims today and University of Michigan’s consumer survey on Friday.

In China overnight we got the latest deflation data. Focus was on the disappointing deflationary print in October’s CPI (-0.2% year-on-year versus -0.1% expected). But given the industry-orientated nature of China’s economy, it is in PPI, not CPI, we are first likely to see a recovery in China’s economy.

PPI’s slow recovery stalled (October’s was -2.6% versus -2.5% the previous month), but the rise in China’s bond yields anticipates PPI should continue rising in the coming months, as both fiscal and monetary stimulus take further effect.

Tellingly, China’s stock market did not sell off on the data, closing up on the day. As discussed Wednesday, Chinese stocks may be putting in a bottom.

Tyler Durden Thu, 11/09/2023 - 09:20

Read More

Continue Reading

Spread & Containment

Novavax’s troubles continue as Covid vaccine maker plans another $300M+ in cost-cutting

Novavax, which has been reeling from a slow rollout of its Covid-19 vaccine compared to the mRNA makers, said it will once again cut costs.
Like Pfizer,…

Published

3 hours ago

on

November 9, 2023

By

Novavax, which has been reeling from a slow rollout of its Covid-19 vaccine compared to the mRNA makers, said it will once again cut costs.

Like Pfizer, BioNTech and Moderna, the Gaithersburg, MD-based company is adjusting to a world in which the virus turns endemic and vaccine uptake isn’t as swift as it was in the early years of the pandemic. Now, Novavax is “prepared to initiate” more than $300 million in cost-cutting next year to “align company scope and structure with future Covid-19 market opportunity,” the company said Thursday in its third-quarter update.

Novavax slashed $950 million, or 47%, of its operating expenses in the first nine months of 2023 as revenue for the quarter fell to $187 million, down from $735 million in the same period last year.

The announcement follows a rough year for the vaccine manufacturer, which went decades without a product on the market but had its fortunes turned around during the pandemic, when it received about $1.6 billion in federal funding. To try to match the pace of its pandemic peers, Novavax grew headcount from 165 workers in 2020 to 1,992 in mid-February of this year, per SEC filings.

But with its protein-based Covid vaccine, dubbed Nuvaxovid, arriving much later than the mRNA shots after multiple delays, that meant Novavax didn’t gather as much market share and revenue. Earlier this year, it began trimming drastically, with a going-concern red flag, then $50 million in cost-cutting, followed by laying off about 25% of its staff.

John Jacobs

“With the delayed start of respiratory vaccinations, we believe we have yet to reach the midpoint of the vaccination season and, with early and encouraging signs of demand for our vaccine, we believe there remains opportunity to deliver doses and grow our share,” John Jacobs, who joined as president and CEO in January, said in a statement. “This reinforces our belief that the long-term Covid-19 market represents a sustainable opportunity for Novavax in the years to come.”

The company’s updated Covid-19 shot received FDA authorization and European Commission clearance last month. Like Moderna and Pfizer/BioNTech, it is also aiming to bring a Covid and flu combination vaccine to market. Novavax plans to start a Phase III trial of the combo shot next year, with a potential accelerated approval and launch two years later, it said Thursday. Moderna began its Phase III last month, and BioNTech said Oct. 26 that it will also enter late-stage testing “in the coming months.”

Novavax had about $666 million in cash at the end of September after a $143 million at-the-market offering last quarter.

Read More

Continue Reading

International

Novavax’s troubles continue as Covid vaccine maker plans another $300M+ in cost-cutting

Novavax, which has been reeling from a slow rollout of its Covid-19 vaccine compared to the mRNA makers, said it will once again cut costs.
Like Pfizer,…

Published

3 hours ago

on

November 9, 2023

By

Novavax, which has been reeling from a slow rollout of its Covid-19 vaccine compared to the mRNA makers, said it will once again cut costs.

Like Pfizer, BioNTech and Moderna, the Gaithersburg, MD-based company is adjusting to a world in which the virus turns endemic and vaccine uptake isn’t as swift as it was in the early years of the pandemic. Now, Novavax is “prepared to initiate” more than $300 million in cost-cutting next year to “align company scope and structure with future Covid-19 market opportunity,” the company said Thursday in its third-quarter update.

Novavax slashed $950 million, or 47%, of its operating expenses in the first nine months of 2023 as revenue for the quarter fell to $187 million, down from $735 million in the same period last year.

The announcement follows a rough year for the vaccine manufacturer, which went decades without a product on the market but had its fortunes turned around during the pandemic, when it received about $1.6 billion in federal funding. To try to match the pace of its pandemic peers, Novavax grew headcount from 165 workers in 2020 to 1,992 in mid-February of this year, per SEC filings.

But with its protein-based Covid vaccine, dubbed Nuvaxovid, arriving much later than the mRNA shots after multiple delays, that meant Novavax didn’t gather as much market share and revenue. Earlier this year, it began trimming drastically, with a going-concern red flag, then $50 million in cost-cutting, followed by laying off about 25% of its staff.

John Jacobs

“With the delayed start of respiratory vaccinations, we believe we have yet to reach the midpoint of the vaccination season and, with early and encouraging signs of demand for our vaccine, we believe there remains opportunity to deliver doses and grow our share,” John Jacobs, who joined as president and CEO in January, said in a statement. “This reinforces our belief that the long-term Covid-19 market represents a sustainable opportunity for Novavax in the years to come.”

The company’s updated Covid-19 shot received FDA authorization and European Commission clearance last month. Like Moderna and Pfizer/BioNTech, it is also aiming to bring a Covid and flu combination vaccine to market. Novavax plans to start a Phase III trial of the combo shot next year, with a potential accelerated approval and launch two years later, it said Thursday. Moderna began its Phase III last month, and BioNTech said Oct. 26 that it will also enter late-stage testing “in the coming months.”

Novavax had about $666 million in cash at the end of September after a $143 million at-the-market offering last quarter.

Read More

Continue Reading

Trending